TUMOR INSTITUTE CCOP

描述：(申请者描述)湾区肿瘤研究所社区 临床肿瘤学计划(BATI-CCOP)是由七个社区和 加州大奥克兰地区的县医院。因为它的 1979年作为CGOP创建，1989年转换为CCOP状态，这 该财团不断为社区提供癌症专家， 初级保健医生和拥有NCI的医院-批准和资助 临床试验计划。 有针对性地整合卫生部出版物《健康人2000》的目标 阿拉米达县少数民族、低收入和女性人口及其主要群体 在奥克兰的城市，BATI-CCOP使癌症患者和普通民众能够 “风险”人群参与治疗和癌症控制研究 SWOG、NSABP和CCG。在其成就的基础上，长期 BATI-CCOP的目标和具体目标包括治疗收益 审判费率高于可比CCOP，少数人和 儿科患者的侵袭性癌症发病率高于其他所有CCOP患者 控制招聘和应计费用超过NCI的癌症控制要求， 加强与研究基地的互动，并继续履行 NCI的《合作条款》。 CCOP将继续100%获得所有符合条件的儿科肿瘤学 该地区的患者，该县95%的合格癌症患者 医院，并实现少数民族和女性参与率将超过75% 在CCOP应计总额中。CCOP也将继续超过NCI 授权并保持旧金山湾区癌症预防和收益方面的领先地位 对照试验。 BATI-CCOP提供了成功的长期记录，并有组织和 来自医学界，经验丰富的内科研究人员， 来自湾区肿瘤研究所的机构和财政支持，以及 非同寻常的机会接触到非裔美国人、西班牙裔、亚洲人、儿科医生，服务不足 和女性人口。

DESCRIPTION: (Applicant Description) The Bay Area Tumor Institute Community Clinical Oncology Program (BATI-CCOP) is a consortium of seven community and county hospitals in the Greater Oakland, California, area. Since its creation in 1979 as a CGOP and its conversion to CCOP status in 1989, this consortium has continuously provided the community's cancer specialists, primary care physicians, and hospitals with an NCI-approved and funded clinical trials program. Integrating the goals of DHHS publication "Healthy People 2000" by targeting minority, low income and female populations in Alameda County and its main city, Oakland, the BATI-CCOP enables cancer patients and the general "at risk" population to participate in therapeutic and cancer control research of SWOG, NSABP and CCG. Building on its achievements, the long-term objectives and specific aims of the BATI-CCOP include accrual to therapeutic trials at higher rates than comparable CCOP's, accrual of minority and pediatric patients at higher rates than all other CCOP's, aggressive cancer control recruitment and accrual exceeding NCI's cancer control requirements, increased interaction w i t h research bases, and continued fulfillment of NCI's "Terms of Cooperation". The CCOP will continue to accrue 100% of all eligible pediatric oncology patients in the region, 95% of all eligible cancer patients at the county hospital, and achieve minority and female participation that will exceed 75% of the total CCOP accrual. The CCOP will also continue to exceed NCI mandates and remain the Bay Area leader in accrual to cancer prevention and control trials. The BATI-CCOP offers a successful long-term track record, and organized and c o m mitted medical community, experienced physician investigators, institutional and financial support from the Bay Area Tumor Institute, and unusual access to African American, Hispanic, Asian, pediatric, underserved and female populations.